Intraosseous squamous cell carcinoma associated with denosumab-induced osteonecrosis of the jaw

0Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) has been associated with the use of different drugs administered in the treatment of malignant neoplasms or metastases and in antiresorptive therapies. Since 2010, denosumab, a monoclonal antibody whose mechanism of action is to prevent the activation of the RANK receptor on the surface of osteoclasts, has been associated with osteonecrosis of the jaw. Primary intraosseous squamous cell carcinoma (PIOSCC) is a rare neoplasm characterised by the presence of squamous cells within the maxillary or mandibular bone without an initial clinical association with the oral mucosa. We present a case of a PIOSCC in an osteonecrosis of the jaw related to a patient who received antiresorptive treatment with denosumab outlining the clinical and histopathological features of MRONJ and PIOSCC.

Cite

CITATION STYLE

APA

Martínez, S. B., Cuéllar, C. N., Vila, C. N., Weiss, E. P., Romanyá, R. P., de Velasco, Á. D. A. F., … Cuéllar, I. N. (2021). Intraosseous squamous cell carcinoma associated with denosumab-induced osteonecrosis of the jaw. Applied Sciences (Switzerland), 11(16). https://doi.org/10.3390/app11167646

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free